The Future of the NDMM: Comparing Emergent Regimens and Understanding Unmet Needs
Dr. Costa and Dr. Schmidt consider promising emergent treatment options and current unmet needs in the NDMM treatment landscape.
Video Player is loading.
EP: 1.An Introduction to NDMM: Treatment Options and Patient Risk Stratification
EP: 2.Clinical Insights from the Results of the MASTER Trial
EP: 3.Key Data and Outcomes from the GRIFFIN Trial
EP: 4.A Practical Approach to Treatment Selection for Patients with NDMM
EP: 5.Optimizing Consolidation and Maintenance Therapy in the NDMM Treatment Landscape
Now Viewing
EP: 6.The Future of the NDMM: Comparing Emergent Regimens and Understanding Unmet Needs
EP: 7.Recap: Available Treatment Options in Transplant-Eligible Multiple Myeloma
Recent Videos
NALIRIFOX In Practice: Treatment Strategies for Patients With mPDAC
Evaluating the Impact of UGT1A128 Status on Tolerability Of NALIRIFOX in mPDAC
NAPOLI-3 in Real World Practice: Expert Insights on Data From ASCO GI 2025
Managing AEs Associated With the FOLFIRINOX and NALIRIFOX Regimens in Pancreatic Cancer
Insights From The NAPOLI-3 and PRODIGE4 Trials In Metastatic Pancreatic Adenocarcinoma
First-Line Treatment Options for Metastatic Pancreatic Adenocarcinoma
Future of HER2-Directed Tumor-Agnostic Therapies
Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage
Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
